ClinicalTrials.gg
TerminatedNCT06304740Updated Dec 12, 2024

Safety and Pharmacokinetics of Subcutaneous Dose of IMG-007 in Healthy Participants

A Phase 1 interventional study of IMG-007 and Placebo in Healthy Volunteers, sponsored by Inmagene LLC. Terminated at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-12.

Sponsored by Inmagene LLC · Phase 1, Interventional, and Treatment

Why this study was terminated
Cohorts 1 and 2 were completed. Cohort 3 was cancelled because it was no longer necessary based on information from another study. No safety concerns were noted.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a double-blind, randomized, placebo-controlled study to assess the safety and PK profile of a single subcutaneous dose of IMG-007 in healthy participants. The study will comprise of a 5-week screening period, a 3-day In-patient Period in a clinical research unit (CRU) and an Out-patient Follow-up Period up to 127 days. The study will include 3 dose cohorts which will be enrolled sequentially. Participants will receive a single subcutaneous dose of IMG-007 or placebo at Baseline according to their assigned dose.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Inmagene LLC is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • (BMI) greater than or equal to 18.0 kg/m2 and less than or equal to 32 kg/m2, and a minimum body weight of 50 kg for males and 45 kg for females
  • Able to participate and comply with all study procedures and restrictions, and willing to provide written to participate in the study.
  • Female participants who are not pregnant or breastfeeding and meet at least one of the following conditions: not of or of childbearing potential and agrees to use a highly effective method of .
  • Male participants who agree to practice true abstinence or agree to use highly effective methods of contraception with female partners of childbearing potentials or are surgically sterilized.

Exclusion Criteria:

  • Conditions or laboratory abnormality that could increase the risk associated with study participation or could interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into the study.
  • Major surgery ≤ 4 weeks before the Baseline Visit or planned major surgical procedure during the study.
  • Use of any prescription medication (except for hormonal contraceptives for female participants within the 14 days prior to the first dose.
  • Drug or alcohol abuse.
  • Use of more than 5 tobacco/nicotine-containing products per month within 3 months of the first dose.
  • , , or infection.
  • Evidence of latent tuberculosis (TB) or a history of untreated or inadequately treated TB infection.
  • Receipt of a live/ within 2 months prior to Baseline Visit.
  • to study treatment or other biologics
  • Participation in prior IMG-007 study or another research study involving an product within 30 days (small molecule) or 3 months (biological product), or 5 half-lives (whichever is longer) prior to the Baseline (Day 1) Visit.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    IMG-007 Cohort 1 (Healthy Participant)

    Cohort 1 will receive a single subcutaneous dose of IMG-007 Dose 1 or matching placebo.

    Drug: IMG-007 · Drug: Placebo

  • Experimental
    IMG-007 Cohort 2 (Healthy Participant)

    Cohort 2 will receive a single subcutaneous dose of IMG-007 Dose 2 or matching placebo.

    Drug: IMG-007 · Drug: Placebo

  • Experimental
    IMG-007 Cohort 3 (Healthy Participant)

    Cohort 3 will receive a single subcutaneous dose of IMG-007 Dose 3 or matching placebo.

    Drug: IMG-007 · Drug: Placebo

Interventions

  • Subcutaneous injection of IMG-007

  • DrugPlacebo

    Subcutaneous Injection of Placebo

06

What researchers measure

Primary outcomes

  1. Adverse Event Evaluation

    Incidence of adverse events emergent from a single subcutaneous dose of IMG-007 in healthy participants.

    Time frame: Up to 18 weeks

Secondary outcomes

  1. Pharmacokinetic Parameters, Cmax

    Peak serum concentration following the administration of a single subcutaneous dose of IMG-007

    Time frame: Up to 18 weeks

  2. Pharmacokinetic Parameters, Tmax

    Time to peak serum concentration following the administration of a single subcutaneous dose of IMG-007

    Time frame: Up to 18 weeks

  3. Pharmacokinetic Parameters, AUC0-t

    Area under the concentration-time curve from time 0 until the last observed concentration following the administration of a single subcutaneous dose of IMG-007

    Time frame: Up to 18 weeks

07

Study locations

1 site
  • Linear Clinical Research
    Perth, Australia
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2024 to primary completion in Aug 2024, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2024
First posted
Mar 12, 2024
StartActual
Mar 6, 2024
Primary completionActual
Aug 28, 2024
CompletionActual
Aug 28, 2024
Last update
Dec 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06304740
Lead sponsor
Inmagene LLC
Responsible party
Sponsor
First posted
Mar 12, 2024
Start date
Mar 6, 2024
Primary completion
Aug 28, 2024
Completion
Aug 28, 2024
Last update
Dec 12, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IMG-007

Start the discussion